

AMENDMENTS TO THE CLAIMS

1-40. (Canceled)

41. (Previously presented) A method for increasing adiponectin production in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more HMG-CoA reductase inhibitor(s).

42. (Canceled)

43. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

44. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.

45. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

46. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin.

47. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is pravastatin.

48. (Previously presented) A method for treatment of hypoadiponectinemia in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s).

49-54. (Canceled)

55. (Currently amended) The method according to ~~any one of claims 48 to 54~~ claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin.

56. (Currently amended) The method according to ~~any one of claims 48 to 54~~ claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

57. (Currently amended) The method according to any one of claims 41[[, 42,]] and [[48-54]]48, wherein the warm-blooded animal is a human.

58. (Canceled)

59. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin, and wherein the warm-blooded animal is a human.

60. (Currently amended) The method according to claim 41 [[or 42]], wherein the HMG-CoA reductase inhibitor is pravastatin, and wherein the warm-blooded animal is a human.

61. (Currently amended) The method according to ~~any one of claims 48 to 54~~ claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin, and wherein the warm-blooded animal is a human.

62. (Currently amended) The method according to ~~any one of claims 48 to 54~~
claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin, and wherein
the warm-blooded animal is a human.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100